Infliximab vs Ustekinumab in Biologic Naive Crohn's Disease

被引：0
|
作者：
HUANG, X. I. A. O. Y. I. N. G. [1 ]
LI, X. I. A. O. F. E. I. [2 ]
机构：
[1] YiWu Cent Hosp, Emergency Dept, Jinhua, Zhejiang, Peoples R China
[2] YiWu Cent Hosp, Dept Infect Dis, Jinhua, Zhejiang, Peoples R China
来源：
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2022年 / 20卷 / 05期
关键词：
D O I：
10.1016/j.cgh.2021.05.013
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：E1216 / E1216
页数：1
相关论文
共 50 条
  • [21] Combination therapy with infliximab and a thiopurine vs. infliximab monotherapy in Crohn's disease
    Luber, R. P.
    Kariyawasam, V. C.
    Dawson, L. P.
    Munari, S. C.
    Sparrow, P. R. Gibson M. P.
    Ward, M. G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 141 - 142
  • [22] Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis
    Narula, Neeraj
    Wong, Emily C. L.
    Marshall, John K.
    Colombel, Jean-Frederic
    Dulai, Parambir S.
    Reinisch, Walter
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (07) : 1588 - +
  • [23] THE COST-EFFECTIVENESS OF USTEKINUMAB COMPARED TO INFLIXIMAB AND ADALIMUMAB IN ADULT PATIENTS WITH MODERATE-SEVERE CROHN'S DISEASE (TNF NAIVE POPULATION)
    Aliyev, E. R.
    Hay, J. W.
    Hwang, C.
    VALUE IN HEALTH, 2018, 21 : S84 - S84
  • [24] Comparison of Surgery Rates in Biologic-Naive Patients With Crohn's Disease Who Were Treated With Vedolizumab or Ustekinumab: Findings From SOJOURN
    Vu, Michelle
    Ghosh, Sabyasachi
    Umashankar, Kandavadivu
    Chastek, Benjamin
    Candela, Ninfa
    Weber, Laura A.
    Landis, Christina
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S715 - S716
  • [25] USTEKINUMAB HAS COMPARABLE LONG-TERM EFFECTIVENESS AS ANTI-TNF AGENTS IN BIOLOGIC-NAIVE PATIENTS WITH CROHN'S DISEASE
    Shiga, Hisashi
    Moroi, Rintaro
    Makuuchi, Motoki
    Takahashi, Takahiro
    Shimoyama, Yusuke
    Kuroha, Masatake
    Kakuta, Yoichi
    Kinouchi, Yoshitaka
    Masamune, Atsushi
    GASTROENTEROLOGY, 2022, 162 (07) : S1084 - S1084
  • [26] Comparison of infliximab with adalimumab in biologic-naive patients with Crohn's disease: a single-center 13-year experience
    Erdogan, C.
    Durak, M. B.
    Alkan, A.
    Kilic, V.
    Kivrakoglu, F.
    Kosar, K.
    Yuksel, I.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (12) : 5757 - 5766
  • [27] Comparison of infliximab with adalimumab in 827 biologic-naive patients with Crohn's disease: a population-based Danish cohort study
    Singh, S.
    Andersen, N. N.
    Andersson, M.
    Loftus, E. V., Jr.
    Jess, T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (05) : 596 - 604
  • [28] Efficacy of Ustekinumab in Ileum-Dominant vs Colonic Crohn's Disease
    Grandhe, Sirisha
    Yang, Nuen T.
    Taylor, Sandra L.
    Mao, Eric J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S441 - S442
  • [29] USTEKINUMAB IN PEDIATRIC CROHN'S DISEASE
    Dilillo, A.
    Civitelli, F.
    Oliva, S.
    Votto, M.
    Aloi, M.
    Isoldi, S.
    Mallardo, S.
    Rossi, P.
    Viola, F.
    Cucchiara, S.
    DIGESTIVE AND LIVER DISEASE, 2015, 47 : E262 - E263
  • [30] Ustekinumab to treat Crohn's disease
    Gisbert, Javier P.
    Chaparro, Maria
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2017, 40 (10): : 688 - 698
12345